Inside the Verve Therapeutics offices (Kyle LaHucik for Endpoints News)
June 15, 2023 06:30 AM EDTUpdated 01:18 PM
Deals
Pharma
Cell/Gene Tx

Verve snags $60M from Lil­ly to tack­le Lp(a) with one-time gene edit­ing

Kyle LaHucik

Senior Reporter

Eli Lil­ly has tapped an­oth­er gene edit­ing part­ner, this time look­ing to go af­ter a large pa­tient pop­u­la­tion in the car­dio­vas­cu­lar space with the help …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times